Results 31 to 40 of about 1,862,769 (263)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy

Cancers, 2021
Simple Summary Oncolytic viruses (OVs) are viruses that selectively target and kill cancer cells while sparing normal ones. OVs are from diverse families of viruses, but naturally occurring OVs have been genetically engineered due to their limitations in
Masmudur M. Rahman, G. McFadden
semanticscholar   +1 more source

Oncolytic viruses: challenges and considerations in an evolving clinical landscape.

Future Oncology, 2022
Despite advances in treatment, cancer remains a leading cause of death worldwide. Although treatment strategies are continually progressing, cancers have evolved many mechanisms for evading therapies and the host immune system.
U. Lauer, Julia Beil
semanticscholar   +1 more source

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

Frontiers in Cellular and Infection Microbiology, 2022
Oncolytic virus therapy has advanced rapidly in recent years. Natural or transgenic viruses can target tumor cells and inhibit tumor growth and metastasis in various ways without interfering with normal cell and tissue function.
Qingbo Li, Patrick Kwabena Oduro, Rui Guo, Rui Guo, Ruiqiao Li, Ling Leng, Xianbin Kong, Qilong Wang, Long Yang, Long Yang   +9 more
doaj   +1 more source

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

Journal of Hematology & Oncology, 2021
Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities have so far ...
Johannes P. W. Heidbuechel, C. E. Engeland   +1 more
semanticscholar   +1 more source

Study of Oncolytic Virus Preservation and Formulation

Pharmaceuticals, 2023
In recent years, oncolytic viruses (OVs) have emerged as an effective means of treating cancer. OVs have multiple oncotherapeutic functions including specifically infecting and lysing tumor cells, initiating immune cell death, attacking and destroying ...
Lina Pan, Xiyu Liu, Dianfa Fan, Zhangbo Qian, Xinjun Sun, Pan Wu, Liping Zhong   +6 more
doaj   +1 more source

Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option

Frontiers in Immunology, 2022
Immunotherapy is one of the promising strategies in the treatment of oncology. Immune checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical treatment of patients with pMMR/MSS/MSI-L mCRC alone.
Yinan Ren, Jiameng Miao, Yuan-Yuan Wang, Z. Fan, X. Kong, Long Yang, Gong Cheng   +6 more
semanticscholar   +1 more source

Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors [PDF]

Zhongguo aizheng zazhi
The oncolytic virus (OV) therapy utilizes natural or genetically modified viruses to specifically target and infect tumor cells, leading to the destruction of cancer cells by the replication of the virus itself.
LIANG Yingyun, CHEN Jianhua
doaj   +3 more sources

A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy

Frontiers in Molecular Biosciences, 2022
Background: Although several oncolytic viruses have already been tested in early-stage clinical studies of breast cancer, there is still an urgent need to develop patient-derived experimental systems that mimic the response of breast cancer to oncolytic ...
Mary E. Carter, Andreas D. Hartkopf, Anna Wagner, Léa L. Volmer, Sara Y. Brucker, Susanne Berchtold, Susanne Berchtold, Ulrich M. Lauer, Ulrich M. Lauer, André Koch   +9 more
doaj   +1 more source

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors

Molecular Therapy: Oncolytics, 2016
To target oncolytic measles viruses (MV) to tumors, we exploit the binding specificity of designed ankyrin repeat proteins (DARPins). These DARPin-MVs have high tumor selectivity while maintaining excellent oncolytic potency.
Jan RH Hanauer, Lisa Gottschlich, Dennis Riehl, Tillmann Rusch, Vivian Koch, Katrin Friedrich, Stefan Hutzler, Steffen Prüfer, Thorsten Friedel, Kay-Martin Hanschmann, Robert C Münch, Christian Jost, Andreas Plückthun, Klaus Cichutek, Christian J Buchholz, Michael D Mühlebach   +15 more
doaj   +1 more source

High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency

Molecular Therapy: Oncolytics, 2019
Measles virus (MeV) is naturally cytolytic by extensive cell-to-cell fusion. Vaccine-derived MeV is toxic for cancer cells and is clinically tested as oncolytic virus.
Jan R.H. Hanauer, Vivian Koch, Ulrich M. Lauer, Michael D. Mühlebach   +3 more
doaj   +1 more source